Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19

BNT162b2 mRNA疫苗接种后,未感染者和新冠肺炎康复者之间的细胞和体液功能反应存在纵向差异。

阅读:12
作者:Roberto Lozano-Rodríguez ,Jaime Valentín-Quiroga ,José Avendaño-Ortiz ,Alejandro Martín-Quirós ,Alejandro Pascual-Iglesias ,Verónica Terrón-Arcos ,Karla Montalbán-Hernández ,José Carlos Casalvilla-Dueñas ,Marta Bergón-Gutiérrez ,José Alcamí ,Javier García-Pérez ,Almudena Cascajero ,Miguel Ángel García-Garrido ,Álvaro Del Balzo-Castillo ,María Peinado ,Laura Gómez ,Irene Llorente-Fernández ,Gema Martín-Miguel ,Carmen Herrero-Benito ,José Miguel Benito ,Norma Rallón ,Carmen Vela-Olmo ,Lissette López-Morejón ,Carolina Cubillos-Zapata ,Luis A Aguirre ,Carlos Del Fresno ,Eduardo López-Collazo

Abstract

We have analyzed BNT162b2 vaccine-induced immune responses in naive subjects and individuals recovered from coronavirus disease 2019 (COVID-19), both soon after (14 days) and later after (almost 8 months) vaccination. Plasma spike (S)-specific immunoglobulins peak after one vaccine shot in individuals recovered from COVID-19, while a second dose is needed in naive subjects, although the latter group shows reduced levels all along the analyzed period. Despite how the neutralization capacity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mirrors this behavior early after vaccination, both groups show comparable neutralizing antibodies and S-specific B cell levels late post-vaccination. When studying cellular responses, naive individuals exhibit higher SARS-CoV-2-specific cytokine production, CD4+ T cell activation, and proliferation than do individuals recovered from COVID-19, with patent inverse correlations between humoral and cellular variables early post-vaccination. However, almost 8 months post-vaccination, SARS-CoV-2-specific responses are comparable between both groups. Our data indicate that a previous history of COVID-19 differentially determines the functional T and B cell-mediated responses to BNT162b2 vaccination over time.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。